Financial Results for Quarter and Half Year ended September 30, 2025
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Remedium Lifecare Limited reported standalone Q2 FY26 revenue from operations of ₹857.79 lakhs, sharply down from ₹2,508.15 lakhs in Q2 FY25. Standalone H1 FY26 profit after tax collapsed to ₹20.12 lakhs from ₹314.80 lakhs in H1 FY25. On a consolidated basis, Q2 FY26 revenue was ₹11,105.82 lakhs with profit after tax of ₹862.34 lakhs, while H1 FY26 PAT came in at ₹1,327.22 lakhs. Total assets stood at ₹1,52,931.68 lakhs (standalone) with borrowings of ₹1,08,754.82 lakhs against equity of just ₹9,085.18 lakhs, indicating a very high leverage profile. The statutory auditor (Taori Sandeep & Associates) issued an unqualified limited review report on both standalone and consolidated results. Subsidiary Remlife Global PTE contributed significant revenue and profit to the consolidated numbers.
Sharp YoY decline in standalone revenue and profit points to weakness in the core business, while the consolidated picture is propped up by an unreviewed subsidiary. The very high debt-to-equity ratio (roughly 12x on standalone books) is a key risk factor for shareholders and may weigh on the stock.